Kangtai Biology: Received the summary report of the clinical trial of freeze-dried live attenuated varicella vaccine.


Release time:

2022-04-16

On March 23, Kangtai biology announced that its wholly-owned subsidiary Minhai biology recently received the summary report of phase I and phase III clinical trials of freeze dried live attenuated varicella vaccine, and the clinical research phase of freeze dried live attenuated varicella vaccine developed by Minhai biology was successfully completed. The results showed that the freeze-dried live attenuated varicella vaccine developed by Minhai Biological has good immunogenicity and safety for healthy varicella susceptible people aged 1 to 55 years.

On March 23, Kangtai biology announced that its wholly-owned subsidiary Minhai biology recently received the summary report of phase I and phase III clinical trials of freeze dried live attenuated varicella vaccine, and the clinical research phase of freeze dried live attenuated varicella vaccine developed by Minhai biology was successfully completed. The results showed that the freeze-dried live attenuated varicella vaccine developed by Minhai Biological has good immunogenicity and safety for healthy varicella susceptible people aged 1 to 55 years.

Freeze-dried live attenuated varicella vaccine is made by inoculating human diploid cells with varicella-zoster virus, culturing, harvesting the virus fluid, adding suitable stabilizers and freeze-drying. The vaccine is suitable for healthy people who are susceptible to varicella from 1 to 55 years old. After vaccination, it can stimulate the body to produce immunity against varicella-zoster virus for the prevention of varicella. Varicella is mainly transmitted by respiratory droplets and contact, and the infection rate is high. Vaccination of varicella vaccine is the most effective means to prevent varicella infection, and it is also one of the vaccines with the highest vaccination rate among non-immunization programs.

At present, domestic manufacturers of live attenuated varicella vaccines include Changchun Baike Biotechnology Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Changchun Qijian Biological Products Co., Ltd., Kexing (Dalian) Vaccine Technology Co., Ltd. and Shanghai Rongsheng Biological Pharmaceutical Co., Ltd. Clinical studies have shown that the product has good safety, immunogenicity and immune persistence.